Acchiardo SR, Moore L, Smith SO, Burk LB, Smith SJ, Will K
Role of endogenous erythropoietin in the hematopoietic
response to iron administration in hemodialysis patients
Am Soc Nephrol
J Am Soc Nephrol (abstract)
(Nov) 6:571 1995
These investigators administered iv iron to HD patients (not on EPO) with
varying degrees of endogenous EPO production. The primary endpoint was
change
in hematocrit. In patients with EPO levels of >10 mU/ml, the administration
of iv iron led to an increase in hematocrit from 20.2% to 27.4%.
Comment: This small study provides intriguing evidence that in
patients with
significant endogenous EPO production, therapy with EPO may not be necessary
if iron stores are adequate. This finding would certainly need to be
confirmed in larger studies.
(Fishbane)
To go back use the BACK button on your browser.
Otherwise click on the desired link to this article below:
Am Soc Nephrol
CRF by problem area :
Anemia/Erythropoietin/Iron